Is Agomelatine Associated with Less Sedative-Hypnotic Usage in Patients with Major Depressive Disorder? A Nationwide, Population-Based Study
Shih-Chun Hsing,1,2 Yo-Ting Jin,3,4 Nian-Sheng Tzeng,5,6 Chi-Hsiang Chung,7– 9 Tien-Yu Chen,5,10,11 Hsin-An Chang,5,6 Yu-Chen Kao,5,12 Wu-Chien Chien4,7– 9 1Center for Healthcare Quality Management, Cheng Hsin General Hospital, Taipei, Taiwan; 2Department of Health Care Managemen...
Guardado en:
Autores principales: | Hsing SC, Jin YT, Tzeng NS, Chung CH, Chen TY, Chang HA, Kao YC, Chien WC |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8741e2f298ae4b1bb53d92aedb54cef4 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Oral bioavailability enhancement of agomelatine by loading into nanostructured lipid carriers: Peyer’s patch targeting approach
por: Prajapati JB, et al.
Publicado: (2018) -
Low-Frequency versus High-Frequency Ultrasound-Mediated Transdermal Delivery of Agomelatine-Loaded Invasomes: Development, Optimization and in-vivo Pharmacokinetic Assessment
por: Tawfik MA, et al.
Publicado: (2020) -
Agomelatine versus paroxetine in treating depressive and anxiety symptoms in patients with chronic kidney disease
por: Chen JW, et al.
Publicado: (2018) -
Agomelatine in the treatment of mild-to-moderate depression in patients with cardiovascular disease: results of the national multicenter observational study PULSE
por: Medvedev VE
Publicado: (2017) -
Mind your state: Insights into antidepressant nonadherence
por: De Wet Wolmarans, et al.
Publicado: (2016)